Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Protocol TOP-Study (tacrolimus organ perfusion): a prospective randomized multicenter trial to reduce ischemia reperfusion injury in transplantation of marginal liver grafts with an ex vivo tacrolimus perfusion.

Pratschke S, Eder M, Heise M, Nadalin S, Pascher A, Schemmer P, Scherer MN, Ulrich F, Wolters H, Jauch KW, Wöhling D, Angele MK.

Transplant Res. 2013 Mar 4;2(1):3. doi: 10.1186/2047-1440-2-3.

2.

Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms.

Dusting GJ, Akita K, Hickey H, Smith M, Gurevich V.

Br J Pharmacol. 1999 Sep;128(2):337-44.

3.

FK506 augments activation-induced programmed cell death of T lymphocytes in vivo.

Migita K, Eguchi K, Kawabe Y, Tsukada T, Mizokami A, Nagataki S.

J Clin Invest. 1995 Aug;96(2):727-32.

4.
5.

Current status of renal transplantation.

Suranyi MG, Hall BM.

West J Med. 1990 Jun;152(6):687-96. Review.

6.

Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium.

Jordan ML, Hignet S, Wright J, Hoffman RA, Starzl TE.

Transplant Proc. 1991 Dec;23(6):2950-2. No abstract available.

7.

Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production.

Henderson DJ, Naya I, Bundick RV, Smith GM, Schmidt JA.

Immunology. 1991 Jul;73(3):316-21.

8.

Antigen presentation and HLA-DR expression by FK-506-treated human monocytes.

Woo J, Propper DJ, Thomson AW.

Immunology. 1990 Dec;71(4):551-5.

10.

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy.

Murase N, Kim DG, Todo S, Cramer DV, Fung JJ, Starzl TE.

Transplantation. 1990 Aug;50(2):186-9.

11.

The influence of FK-506 on the thymus: an immunophenotypic and structural analysis.

Pugh-Humphreys RG, Ross CS, Thomson AW.

Immunology. 1990 Jul;70(3):398-404.

12.

Effects of a novel immunosuppressive agent, FK506, on human B cell activation.

Suzuki N, Sakane T, Tsunematsu T.

Clin Exp Immunol. 1990 Feb;79(2):240-5.

14.

Supplemental Content

Support Center